Table 2 |
||||
|
Incidence of bone metastases and mortality |
||||
| Clodronate (n = 530) |
Placebo (n = 539) |
Hazard ratio (95% CI) |
P value |
|
|
|
||||
| Bone metastases (all patients) |
||||
| 2 years |
19 (3.6%) |
35 (6.5%) |
0.546 (0.312, 0.954) |
0.031 |
| 5 years |
51 (9.6%) |
73 (13.5%) |
0.692 (0.484, 0.990) |
0.043 |
| Bone metastases (stage II/III) |
||||
| n |
352 |
357 |
||
| 2 years |
16 (3.0%) |
32 (6.0%) |
0.496 (0.272, 0.975) |
0.020 |
| 5 years |
39 (7.4%) |
64 (11.8%) |
0.592 (0.398, 0.882) |
0.009 |
| Visceral metastases |
||||
| 2 years |
39 (7.3%) |
47 (8.7%) |
0.84 (0.55,1.29) |
0.428 |
| 5 years |
79 (14.9%) |
94 (17.4%) |
0.84 (0.62,1.13) |
0.241 |
| Visceral metastases (stage II/III) |
||||
| n |
352 |
357 |
||
| 2 years |
34 (9.7%) |
42 (11.8%) |
0.81 (0.52,1.28) |
0.372 |
| 5 years |
64 (18.2%) |
81 (22.7%) |
0.77 (0.56,1.07) |
0.120 |
| Deaths during follow-up (median follow-up, 5.6 years) |
||||
| All patients |
98 (18.5%) |
129 (23.9%) |
0.768 (0.591, 0.999) |
0.048 |
| Stage II/III |
82 (23.3%) |
110 (30.8%) |
0.743 (0.558, 0.989) |
0.041 |
|
|
||||
|
CI, confidence interval. |
||||
|
Powles et al. Breast Cancer Research 2006 8:R13 doi:10.1186/bcr1384 |
||||
